Cullinan Oncology
CGEM
99 hedge funds and large institutions have $467M invested in Cullinan Oncology in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 8 closing their positions.
25,100% more call options, than puts
Call options by funds: $504K | Put options by funds: $2K
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
36% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 28
11% more funds holding
Funds holding: 89 → 99 (+10)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less capital invested
Capital invested by funds: $473M → $467M (-$6.62M)
2.74% less ownership
Funds ownership: 83.91% → 81.18% (-2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$8.15M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.54M |
| 3 |
CA
CHI Advisors
New York
|
+$2.63M |
| 4 |
Goldman Sachs
New York
|
+$2.18M |
| 5 |
BlackRock
New York
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$14.9M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$10.5M |
| 3 |
Millennium Management
New York
|
-$2.32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.8M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
101
Dupont Capital Management
Wilmington,
Delaware
| – | -$145K | -11,348 | Closed |
|
102
Simplex Trading
Chicago,
Illinois
| – | -$3.89K | -289 | Closed |
|
103
Rockefeller Capital Management
New York
| – | -$2K | -221 | Closed |
|
|
AF
104
Allworth Financial
Folsom,
California
| – | -$1K | -46 | Closed |
|
|
PA
105
Parallel Advisors
San Francisco,
California
| – | -$243 | -18 | -64% |
|
CGEM Hedge Fund Activity: Q3 2022 in Review
99 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q3 2022, worth a combined $467M — down 1.4% from $473M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CGEM positions and 8 closed out — a net gain of 10 holders — while 38 added to existing stakes and 28 trimmed.
The largest buyer was Kennedy Capital Management, adding an estimated $8.15M. The largest seller was Baupost Group, cutting an estimated $14.9M.
- 99 institutional investors held Cullinan Oncology (CGEM) as of Q3 2022, up from 89 in Q2 2022.
- Funds reported $467M of Cullinan Oncology stock for Q3 2022, down 1.4% quarter-over-quarter.
- 18 funds opened new Cullinan Oncology positions in Q3 2022 and 8 closed out, a net change of +10 holders.
- The largest Cullinan Oncology buyer in Q3 2022 was Kennedy Capital Management, an estimated $8.15M added.
- The largest Cullinan Oncology seller in Q3 2022 was Baupost Group, an estimated $14.9M sold.
Based on aggregated 13F filings for Q3 2022.